Sugi Predict

Sugi Predict / Targets / SCN5A

SCN5A

Sodium channel protein type 5 subunit alpha · Q14524 · SCN5A on Sugi Atlas →

173,014 patent compounds predicted against SCN5A, 111,798 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL121389 SCHEMBL121389 0.70 10/20
SCHEMBL121689 SCHEMBL121689 0.54 8/20
SCHEMBL121418 SCHEMBL121418 0.52 8/20
SCHEMBL121650 SCHEMBL121650 0.52 8/20
SCHEMBL121564 SCHEMBL121564 0.39 6/20
SCHEMBL86128 SCHEMBL86128 0.47 5/20
Isradipine Isradipine (SCHEMBL34555) 1.00 4/20
(R)-Isradipine (R)-Isradipine (SCHEMBL34556) 1.00 4/20
(S)-Isradipine (S)-Isradipine (SCHEMBL34557) 1.00 4/20
Lemildipine Lemildipine (SCHEMBL49442) 0.62 4/20
Lemildipine Lemildipine (SCHEMBL49443) 0.62 4/20
SCHEMBL121474 SCHEMBL121474 0.49 4/20
SCHEMBL122571 SCHEMBL122571 0.48 4/20
Mexiletine Mexiletine (SCHEMBL16081) 1.00 3/20
(R)-Mexiletine (R)-Mexiletine (SCHEMBL16082) 1.00 3/20
Mexiletine Mexiletine (SCHEMBL42226) 1.00 3/20
SCHEMBL54413 SCHEMBL54413 0.73 3/20
SCHEMBL99680 SCHEMBL99680 0.51 3/20
SCHEMBL49022 SCHEMBL49022 0.48 3/20
SCHEMBL50868 SCHEMBL50868 0.48 3/20

Clinical trials — most relevant to SCN5A by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Carbamazapine for Inherited Erythromelalgia Patients With NaV1.7 Mutations PHASE4COMPLETED
Safety and Tolerability of Lacosamide in Patients With Gain-of-function Nav1.7 Mutations Related Small Fiber Neuropathy PHASE3COMPLETED
A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome PHASE3RECRUITING
A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and Safety PHASE3RECRUITING
An Open-Label Study to Investigate the Safety of Single and Multiple Ascending Doses in Children and Adolescents With Dravet Syndrome PHASE1/PHASE2COMPLETED
Mutation-specific Therapy for the Long QT Syndrome PHASE2COMPLETED
N-of-1 in ATS and MEPPC PHASE2NOT_YET_RECRUITING
Safety and Tolerability Study of ST-503 for Refractory Pain Due to Peripheral Neuropathy (Small Fiber Predominant, SFN) PHASE1/PHASE2RECRUITING
Effects of Mexiletine on Colonic Transit in a Patient With Irritable Bowel Syndrome - Constipation (IBS-C) PHASE1COMPLETED
A Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of SYH2085 PHASE1RECRUITING
Sodium Channel Splicing in Heart Failure Trial (SOCS-HEFT) Prospective Study nanUNKNOWN
Sodium Channel Splicing in Heart Failure Trial nanCOMPLETED
Role of SNP and DIGOXIN Response in Atrial Fibrillation Patients nanCOMPLETED
Evaluation of the Effects of KCNQ1 Mutation on Insulin Tolerance and Obsessive Compulsive Features in Long QT Romano-Ward Syndrome Patients. nanUNKNOWN
Worm Study: Modifier Genes in Sudden Cardiac Death nanUNKNOWN
Sodium Channel Splicing in Obstructive Sleep Apnea (SOCS-OSA) nanCOMPLETED
Genetic Analysis of Heart Channelopathies in Brazilian Patients and Their Relatives nanUNKNOWN
Impact on Risk Stratification of Overlap Syndrome Phenotype in Patients With E1784K Mutation in SCN5A nanCOMPLETED
Development of an Artificial Intelligence Algorithm to Detect Pathological Repolarization Disorders on the ECG and the Risk of Ventricular Arrhythmias nanRECRUITING
MRI-phenotyping of Patients With Pathogenic Anoctamin 5 Variants nanRECRUITING
ST-segment Elevation as an AF Endophenotype nanCOMPLETED
LQT and Smartphone/Smartwatch nanCOMPLETED
Na+ Channel mRNA Regulation in Heart Failure nanCOMPLETED
Treatment of Gait Disorders in Children With Dravet Syndrome nanCOMPLETED
Prospective Identification of Long QT Syndrome in Fetal Life nanCOMPLETED
SCN1A Horizons A Natural History Study of SCN1A-related Epilepsies in the United Kingdom nanRECRUITING
Feasibility of Improving Risk Stratification in Brugada Syndrome nanCOMPLETED
Genetic Determinants of Sudden Cardiac Death nanCOMPLETED
Longitudinal Study of Phenotypic and Developmental Severity in Patients With Dravet Syndrome With SCN1A Gene Mutation nanRECRUITING
Molecular Genetic Screening and Identification of Congenital Arrhythmogenic Diseases nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a SCN5A binder may also engage these)

ProteinNameSimilarity
P15389 — 1.000 P15389 →
Q9JJV9 — 1.000 Q9JJV9 →
Q62968 — 1.000 Q62968 →
SCN10A Sodium channel protein type 10 subunit alpha 1.000 landscape →
Q6QIY3 — 1.000 Q6QIY3 →
P15390 — 1.000 P15390 →
Q28371 — 0.999 Q28371 →
Q9ER60 — 0.997 Q9ER60 →
SCN4A Sodium channel protein type 4 subunit alpha 0.997 landscape →
O46669 — 0.997 O46669 →
SCN2A Sodium channel protein type 2 subunit alpha 0.996 landscape →
P0DMA5 — 0.996 P0DMA5 →
SCN3A Sodium channel protein type 3 subunit alpha 0.996 landscape →
P04775 — 0.995 P04775 →
Q2XVR7 — 0.994 Q2XVR7 →
O88420 — 0.994 O88420 →
CACNA1H Voltage-dependent T-type calcium channel subunit alpha-1H 0.993 landscape →
A2APX8 — 0.993 A2APX8 →
CACNA1G Voltage-dependent T-type calcium channel subunit alpha-1G 0.993 landscape →
B1AWN6 — 0.993 B1AWN6 →
Q6AXP6 — 0.993 Q6AXP6 →
O97531 — 0.993 O97531 →
Q62205 — 0.992 Q62205 →
Q96P56 — 0.992 Q96P56 →
P08104 — 0.992 P08104 →
CACNA1I Voltage-dependent T-type calcium channel subunit alpha-1I 0.992 landscape →
Q9R053 — 0.992 Q9R053 →
Q28644 — 0.992 Q28644 →
O08562 — 0.992 O08562 →
A2ASI5 — 0.991 A2ASI5 →